Abbvie, Inc. (ABBV) Tops Q2 EPS by 6c; Guides Q3 EPS to Strong Side
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
UPDATE: UBS Upgrades Abbvie (ABBV) to Buy
July 28, 2014 8:14 AM EDT(Updated - July 28, 2014 10:40 AM EDT)
UBS upgraded Abbvie (NYSE: ABBV) from Neutral to Buy with a price target of $67 (from $57). Analyst Marc Goodman noted compelling risk/reward.
"Upgrading ABBV to a Buy rating and PT of $67 with 4-fold investment thesis (1) We like the Shire deal. It's accretive, diversifies earnings... More
